TEMENOS
7.1.2020 09:32:05 CET | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that BNP Paribas Securities Services has extended its license for Temenos Multifonds Global Accounting and Temenos Multifonds Global Investor. Temenos’ single, global software platform and integrated operating model will deliver localized accounting and reporting to underpin the management of BNP Paribas Securities Services’ fund administration operations.
BNP Paribas Securities Services has been a partner of Temenos for more than 20 years, initially deploying the Temenos Fund Administration platform in Luxembourg to replace its legacy architecture and deliver the fundamental scalability needed for BNP Paribas to rapidly onboard new countries onto the global platform. By using a scalable platform and enabling more automated exception-based processing, BNP Paribas Securities Services will benefit from greater operational efficiency, reduced costs and new growth opportunities.
As part of this long-standing strategic partnership, Temenos recently completed the integration of Temenos Multifonds Global Accounting into BNP Paribas Securities Services’ domestic fund administration business in France. Achieved in under two years, the project covered 1,300 fund accounts, representing over 20% of the total French market.
Alain Pochet, Head of Client Delivery at BNP Paribas Securities Services, commented: “We are delighted to continue this strategic, long-standing partnership with Temenos. Its investment in R&D means that we will continue to benefit from cutting-edge, next generation banking software, enabling us to enhance operational efficiency and streamline our operating model to enable us to quickly onboard new jurisdictions and grow our business over time.”
Max Chuard, CEO , Temenos, said: “It is a great privilege to continue our ongoing support of BNP Paribas Securities Services as they continue to optimize their global fund administration operations and enhance operational efficiency. Throughout this long-standing partnership, our goals have been consistently aligned to BNP Paribas’ who have adopted our market-leading products to enhance fund administration with sophisticated workflow, production and control techniques. With a 20-year track record for providing leading fund administration software that supports $7 trillion assets and more than 30,000 funds across 30 countries, Temenos has the blueprint for transformative software that delivers greater efficiencies, reduced costs and enables our clients to take advantage of future growth opportunities.”
– Ends –
About BNP Paribas
BNP Paribas Securities Services, a wholly
owned subsidiary of the BNP Paribas Group, is a leading global custodian
and securities services provider. Backed by the strength of the BNP
Paribas Group, we provide multi-asset post-trade and asset servicing
solutions for buy and sell-side market participants, corporates and
issuers. With a global reach covering 90+ markets, our network is one of
the most extensive in the industry, enabling clients to maximise their
investment opportunities worldwide.
https://securities.bnpparibas.com/
About Temenos
Temenos AG (SIX: TEMN), headquartered in
Geneva, is the world’s leader in banking software, partnering with banks
and other financial institutions to transform their businesses and stay
ahead of a changing marketplace. Over 3,000 banks across the globe,
including 41 of the top 50 banks, rely on Temenos to process both the
daily transactions and client interactions of more than 500 million
banking customers. Temenos offers cloud-native, cloud-agnostic front
office and core banking, payments, fund management and wealth management
software products enabling banks to deliver consistent, frictionless
customer journeys and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve industry-leading cost-income ratios of 25.2% and returns on equity of 25.0%, 2X better than the industry average. These clients also invest over 53% of their IT budget on growth and innovation versus maintenance, which is 2.5X the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005107/en/
Contact:
Media Contacts Jessica Wolfe & Grace Collins Temenos Global Public Relations Tel: +1 610 232 2793 & + 44 20 7423 3969 Email : press@temenos.com Alistair Kellie & Andrew Adie Newgate Communications on behalf of Temenos Tel: +44 20 7680 6550 Email: allnewgatetemenos@newgatecomms.com Simon Anderson Narrative on behalf of Temenos Tel: +44 (0)7393 636 982 Email: simon.anderson@narrative.uk.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years27.2.2026 07:00:00 CET | Press release
Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in itch intensity, skin lesions and quality of life1 These results, to be presented at 2026 Winter Clinical™ Miami, mark the longest LTE study in prurigo nodularis reported to date1 Nemluvio is the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis2-5 Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the United States (U.S.) and European Union (EU)4,5 Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results showed
Venture Global Announces New Long-Term LNG Partnership with Hanwha of Korea27.2.2026 01:00:00 CET | Press release
20-year sales and purchase agreement marks Venture Global’s first SPA with a Korean entity Today, Venture Global, Inc. (NYSE: VG) and Hanwha Aerospace Co., Ltd. announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 1.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement brings Venture Global’s long-term contracted portfolio to over 46 MTPA. “Venture Global is thrilled to announce our first long-term supply deal in Korea through a new partnership with Hanwha Aerospace which marks another important step in expanding reliable, long-term LNG supply to our partners in Asia,” said Mike Sabel, CEO of Venture Global. “We are proud to support growing global energy needs with low-cost, secure American LNG while strengthening the strategic energy partnership between the United States and South Korea to support long-term industrial and economic growth.” About Venture Global Ventu
Hydnum Steel Secures 500 MW of Electrical Power, a Key Step Forward in the Construction of Its Clean Steel Plant in Spain27.2.2026 00:00:00 CET | Press release
The company will produce flat steel, a product for which the EU has an annual deficit of almost 11 million tons Hydnum Steel has taken a decisive step towards constructing Spain’s first clean steel plant after being granted access to the electricity grid at the Brazatortas node in the province of Ciudad Real. The company has been granted an electricity capacity of 500 MW, as published in the Official State Gazette, which should be enough to guarantee supply to its electric arc furnace. This concession marks a significant milestone for a pioneering project in the Iberian Peninsula. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225309290/en/ Image recreating the steel plant that Hydnum Steel will build in Puertollano, Spain Hydnum Steel is consolidating its position as a reliable supplier of clean European steel. The fully digitally integrated plant will produce hot-rolled steel coils efficiently and sustainably, with bene
1089 Inc. Partners with Price Forbes and Oka-Lloyd's Syndicate 1922 to Launch Market-Defining First: Carbon Asset Insurance Framework for Transportation and Energy Sectors26.2.2026 23:01:00 CET | Press release
New program introduces dedicated insurance safeguards and immutable transfer infrastructure to advance fiscal maturation of global carbon markets, enabling scaled participation across world's highest-emitting sectors, Transportation and Energy. 1089 Inc., in collaboration with Price Forbes and Oka, The Carbon Insurance Company, announce launch of an insured carbon asset designed to bring institutional safeguards, disciplined financial architecture, and verifiable data integrity to carbon markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226012782/en/ 1089 Inc. is Advancing Carbon™, focused on evolving global carbon markets and decarbonizing the highest-emitting sectors on the planet: Transportation and Energy. The framework provides defined risk coverage for 1089’s CX89 Advanced Fuels Carbon Assets, underwritten by Lloyd’s Syndicate 1922 and placed with the support of Price Forbes and Oka. The program introduces ins
Sun Nuclear QADS 2026 Event Combines Clinical Insight and New Innovations for Advancing Radiation Therapy QA26.2.2026 23:00:00 CET | Press release
15th QA & Dosimetry Symposium convenes medical physics and radiation therapy community in RomeTwo days of sessions span diverse topics from 24 clinical practitioners and thought leadersEvent introduces new Daily QA™ 4 Pro device and features expansion of AI-enabled solutions Sun Nuclear, a Mirion Medical company, today opened the QA & Dosimetry Symposium (QADS), taking place over the next two days in Rome, Italy. The 15th installment brings together more than 230 clinical physicists and radiation medicine professionals from nearly 40 countries. Participants from diverse clinical environments will earn continuing education credits while sharing practical insights, emerging approaches, and real-world experiences shaping the future of quality and patient safety in cancer care. Building on its legacy as a peer-driven forum with practical applications, QADS 2026 features sessions delivered by 24 speakers spanning: Future Directions in Machine and Patient QA and In-vivo Dosimetry Stereotacti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom